FLOT Chemotherapy

DRUG6 trials

Conditions

Chemotherapy EffectEsophageal AdenocarcinomaEsophagogastric JunctionEsophagogastric Junction AdenocarcinomaGastricGastric AdenocarcinomaGastric CancerGastroesophageal Adenocarcinoma

Phase 1

A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma

RecruitingNCT07059299

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestEsophageal Adenocarcinoma, Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma +2

Start: 2025-12-12End: 2027-08-31Target: 18Updated: 2025-12-19

Phase 2

Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer

CompletedNCT03636893

Ruijin HospitalChemotherapy Effect, Gastric Cancer

Start: 2018-08-24End: 2025-05-08Updated: 2025-07-23

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

RecruitingNCT07069712

AstraZenecaGastroesophageal Adenocarcinoma

Start: 2025-07-17End: 2029-07-16Target: 100Updated: 2026-10-16

Phase 3

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Active, not recruitingNCT04592913

AstraZenecaEsophagogastric Junction, Gastrointestinal Neoplasms

Start: 2020-11-17End: 2027-09-27Updated: 2025-12-24

A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.

Not yet recruitingNCT07877818

AstraZenecaEsophagogastric Junction, Gastric

Start: 2026-11-30End: 2029-11-01Target: 140Updated: 2026-10-16

Unknown Phase

Pathological Response to Perioperative FLOT in Gastric Adenocarcinoma

Not yet recruitingNCT07859254

Fundación Santa Fe de BogotaGastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stomach Neoplasms

Start: 2026-10-01End: 2027-10-01Target: 90Updated: 2026-10-05

2026-09-09

Efficacy of durvalumab and safety by treatment period in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy in resectable gastric/gastroesophageal junction (G/GEJ) cancer.

Journal of Clinical Oncology2026-05-27

GEMINI-Perioperative (PeriOp) Gastric: A phase 2 study of novel agent-based combinations as PeriOp therapy for previously untreated, locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma.

Journal of Clinical Oncology2026-01-10

Surgical journey for participants (pts) in the MATTERHORN trial: A global, randomized, phase 3 study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma.

Journal of Clinical Oncology2026-01-10

Analysis of 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) administration in MATTERHORN: A randomized, phase 3 study of durvalumab (D) plus FLOT in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma.

Journal of Clinical Oncology2026-01-10

Neoadjuvant FLOT versus SOX chemotherapy in locally advanced gastric cancer: secondary outcomes of a single-centre, open-label, randomised, exploratory phase 2 trial.

2025-10-05

Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).

Journal of Clinical Oncology2025-06-049 citations

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer

New England Journal of Medicine2025-06-01110 citations

680. P02.06 MATTERHORN PCR BY REGION

Diseases of the Esophagus2024-09-01

Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study.

Journal of Clinical Oncology2024-01-2031 citations

Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial.

2023-09-18110 citations

Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial.

2023-08-1435 citations

MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer

Future Oncology2022-05-10125 citations

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study

Journal for ImmunoTherapy of Cancer2022-03-0198 citations

CT-Based Radiomics Showing Generalization to Predict Tumor Regression Grade for Advanced Gastric Cancer Treated With Neoadjuvant Chemotherapy

Frontiers in Oncology2022-02-2517 citations

MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer—A randomized, double-blind, placebo-controlled, phase 3 study.

Journal of Clinical Oncology2021-05-2030 citations

Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer

Nature Communications2020-11-30111 citations

FLOT Chemotherapy

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Unknown Phase

Related Papers